Grow Your Pile is educational and is not investment advice or a recommendation to buy or sell any security. Options involve risk and are not suitable for every investor.
The one-line read
Two things drove today, and only one of them is durable. A Treasury liquidity operation put an artificial bid under the whole market, and a genuine medical breakthrough — the first successful late-stage mRNA cancer vaccine — sent Merck and Moderna soaring. Underneath both, the same three-day rotation kept running: out of crowded US tech, into everything else.
Story one: the Treasury put a floor under the market this morning
The reason futures gapped higher today is not on any sector screen. The Treasury doubled the size of its liquidity-support buyback operations for longer-dated coupon securities. S&P futures jumped roughly 42 handles on the announcement, the Nasdaq 150, long bonds rallied (TLT +1.6%), and the dollar fell.
What makes this worth leading with is that three of the strategists we follow independently flagged it, and independently called it what it is — a liquidity operation, not organic strength.
Danielle DiMartino Booth (QI Research): “What is bought back at the long end is issued at the short end.” A maturity swap, not debt reduction.
Charlie Bilello (Creative Planning): the “debt buyback” is reshuffling, not reduction — the government is running huge deficits, buying old bonds, issuing more new ones. National debt is up roughly $600 billion since July 1.
Dougie Kass (Seabreeze): “lack of price discovery in both equities and bonds.” He acted on it, too — cut his index shorts hard and covered his QQQ short at $714.77.
When three independent voices converge on the same read, it carries more weight than any single opinion. The takeaway is not “sell” — a Treasury bid is a real bid and can persist. It is that today’s strength was manufactured at the margin, and you should weight it accordingly rather than read it as the market voting confidence.
It also explains why gold and real assets keep bidding no matter what equities do on a given day. If the answer to the debt is more issuance and liquidity operations, hard assets are the hedge against exactly that. Which brings us to the second story, and to gold.
Story two: Merck and Moderna, and the first mRNA cancer vaccine that worked
This one is real, and it is a landmark.
Merck and Moderna jointly announced positive topline Phase 3 results from the INTerpath-001 trial, testing a personalized mRNA-based cancer vaccine — intismeran autogene — in combination with Keytruda, as an adjuvant treatment in melanoma. It is the first successful late-stage study of a personalized mRNA cancer vaccine, and it significantly extended the time patients lived without their cancer returning compared with Keytruda alone.
The market reaction was enormous:
Moderna roughly doubled on the day (reports ranged from +110% to +130%).
Merck posted its best intraday gain since 2009, up over 12%.
Health Care was the best sector on the board at +3.7% — and now you know why. It was not a defensive flight into pharma; it was a specific, validating clinical result in the two companies that own it.
The Wall Street Journal called it “the first successful late-stage mRNA study validating decades of custom-treatment research.” Whatever it eventually means commercially — and that is years and regulatory steps away — today it re-rated a piece of the market on genuine news rather than on a liquidity operation. Those are different kinds of green, and it is worth keeping them separate in your head.
The rotation underneath both: three days of “everything but semis”
Strip out the Treasury bid and the vaccine pop, and the pattern we have tracked since Monday is still running.
Nine of eleven sectors closed green and the Nasdaq was red — for the third straight session — and today the VIX actually fell 2.7%. This is no longer a scared market unwinding; it is an orderly rotation out of a single crowded trade. Health Care +3.7%, Materials +2.0%, Staples +1.6%, Discretionary +1.5%. Defensives and cyclicals rising together, only technology falling.
And it is specific names bleeding, not the index:
But “semis are down” is too blunt. The one name that ripped was Marvell, up 6.6% — the top single-name gainer on the board — after it issued Google a warrant for roughly 59 million shares (about 6.7% of the company) to expand custom-silicon and TPU work. So it is not “chips are broken.” It is the GPU and AI-capex complex under pressure while the custom-silicon supply chain gets rewarded. The market is discriminating inside the sector, not fleeing it wholesale.
Gold broke the ceiling we flagged twice
In the weekend note and again yesterday we named two lines on gold: GLD’s upper Bollinger band at $409.33 and its 200-day average at $412.35 — a shelf about 0.7% wide that it had to clear.
Today GLD is $410.40, up 2.97% — through the band, pressed against the 200-day. Spot gold jumped 3.2% to $4,471.88, and silver ran even harder, up about 3% to $65.18. Our scanner front-ran this: on Monday we flagged gold’s price of risk turning up with the price still flat. Today the price caught the volatility.
The last line standing is the 200-day at $412.35. A close above it, with the average starting to turn up, would be a real change of character rather than another bounce — and it fits the fiscal backdrop the Treasury buyback just underlined.
What our own volatility data shows
We run a scanner across four underlyings every morning that prices the expected move at each tenor. Divide the expected move by the square root of the days and you can compare tenors on a like-for-like basis.
Front-end volatility has now risen three sessions running, and it is a QQQ story. QQQ’s overnight reading has climbed each day since Monday, up about 27% over the three, and its one-week expected move went from roughly 1.6% Monday to 1.9% today. Meanwhile QQQ’s price of risk is running at 1.8 times SPY’s. The market is not pricing broad fear; it is pricing fear in the Nasdaq specifically — exactly where the crowding and the leverage sit.
That is the same signal from a different instrument: the risk is concentrated in tech, not spread across the tape.
Rates, credit and the dollar
Domestic credit is uniformly green — Treasuries, TIPS, municipals, high grade and high yield all higher, with TLT up 1.6% as the buyback lifted the long end. The single exception is convertibles, down 1.2%, and that is the tech story showing up in the bond tape rather than a credit warning: converts are equity-linked and track the Nasdaq.
The dollar fell across the board — euro +0.8%, pound +0.7%, yen strengthening — and that weak-dollar backdrop is the engine under the whole day. Gold, silver, crude, bitcoin and emerging markets all rose together: South Africa +4.0%, Brazil +3.2%, South Korea +2.1%, China +1.6%. Keith McCullough’s feed today was a running list of all-time-high alerts in exactly these places — health care, high-dividend, New Zealand, Colombia, Brazil — under the banner “#GoAnywhere.” When the loudest macro voice on the tape is posting record highs in New Zealand and Colombia while US tech bleeds, the rotation is not our imagination.
The data underneath
Housing continued to weaken, via Liz Ann Sonders: pending home sales fell in all four regions in July — the West down 4.7%, the South down 2.2% — and on a year-over-year basis pending sales turned negative for the first time since January. Import prices cooled to +5.9% year over year from +6.7%. Danielle DiMartino Booth has been pointing at housing and mortgage credit for two weeks now, and the data keeps confirming her.
Worth holding alongside the day’s cheerful tape: Dougie Kass flagged that real disposable income is weakening and the savings rate is running down — “the outlook for the consumer is deteriorating” — and that positioning is stretched, with cash levels the sixth-lowest since 1998 and equity allocations the highest since 2021. “Everyone’s on one side of the boat” is not a timing signal, but it is context for why a Treasury bid was needed to hold things up.
Trusted Voices
Liz Ann Sonders (Schwab) — pending home sales negative year over year for the first time since January, declines in all four regions; import prices cooling to +5.9%.
Keith McCullough (Hedgeye) — a stream of all-time-high alerts in health care, high-dividend, and international (New Zealand, Colombia, Brazil). “#GoAnywhere” — the rotation out of US tech, narrated live.
Charlie Bilello (Creative Planning) — the Treasury “buyback” is reshuffling, not reduction; national debt +$600B since July 1.
Danielle DiMartino Booth (QI Research) — on the buyback, “what is bought back at the long end is issued at the short end”; continues her housing and mortgage-credit thread.
Dougie Kass (Seabreeze) — flagged the buyback as the reason futures gapped, called it a lack of price discovery, and de-risked into it (cut index shorts, covered his QQQ short). Bearish on the consumer and on stretched positioning.
Bottom line
Read today in two layers. On top, a genuine medical breakthrough that deserved its rally — the first mRNA cancer vaccine to succeed in a late-stage trial, worth every point Merck and Moderna gained on it. Underneath, a market held up by a Treasury liquidity operation that three separate strategists called artificial, on a day the VIX fell and nine sectors rose while the Nasdaq alone declined for the third straight session.
The durable signals are the ones that keep repeating regardless of the daily bid: money rotating out of crowded US tech, gold breaking through resistance, the dollar weakening, and the consumer data softening. Those have been consistent for three sessions. The Treasury bid may or may not be there tomorrow.
When part of a day’s strength is engineered, the honest response is not to fight it and not to trust it — it is to keep sizing to what you actually know, and to notice that the market’s most bearish voices were quietly taking risk off into the pop.
Grow Your Pile publishes every options trade in all three portfolios, winners and losers, with entry, exit and running P&L on the member dashboard. Nothing in this note is investment advice or a recommendation to buy or sell any security. Options involve risk and are not suitable for all investors. Market data cited is drawn from intraday prints on August 19, 2026 and is subject to change. Clinical-trial results are topline company announcements and are subject to regulatory review; nothing here is medical advice or a view on any drug. Third-party figures are attributed to their sources and have not been independently audited by us. Past performance is not indicative of future results, and results shown are those of our own accounts and are not representative of any subscriber’s results. Read the Characteristics and Risks of Standardized Options before trading.
Tony Battista and Tony Rihan Grow Your Pile